Getting your Trinity Audio player ready...

Today, most investors are going to focus on those companies that were in the news cycle for one reason or another on Wednesday. One of the companies that could be worth looking into is the global biotech company Dyadic International (NASDAQ: DYAI), which is involved in deploying its innovative medical protein production platforms to meet the growing worldwide protein bio-production demands.

On February 21, 2024, the stock peaked for the month, reaching $1.51, marking an 11.85% increase for the day. Subsequently, the stock dipped below the 50-day moving average (DMA). However, yesterday, it found support at the 20 DMA. This suggests that the stock, which is currently undervalued, warrants close attention in the future.

These proteins are designed to address the demand for cost-effective, accessible, and efficient biopharmaceuticals for both animal and human health needs. On Wednesday, Dyadic International’s Dutch subsidiary, Dyadic Nederland BV, revealed a strategic collaboration with Rabian BV, a Netherlands-based SME founded by vaccine experts and experienced entrepreneurs. This partnership aims to develop scalable, cost-effective, and potent abies prophylactics and vaccines using Dyadic’s CI protein production platform.

Through their collaboration, the two organizations aim to tackle the worldwide issue of rabies, a highly infectious disease responsible for tens of thousands of deaths annually. Rabian has secured a total of 1.7 million euros from Eurostars for the Avatar project, leveraging its expertise in virology to develop a rabies vaccine.

Under the project, Rabian will utilize Dyadic’s C1 platform. According to the terms of their agreement, Dyadic will receive an equity share in the project and royalties upon commercialization of the product. Dyadic’s CEO, Mark Emelfarb, also commented on the collaboration, expressing enthusiasm about the prospect of furthering their longstanding relationship with Rabian.